Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial
Jean Bennett(University of Pennsylvania), Jennifer Wellman(Children's Hospital of Philadelphia), Kathleen Marshall(Children's Hospital of Philadelphia), Sarah McCague(Children's Hospital of Philadelphia), Manzar Ashtari(University of Pennsylvania), Julie DiStefano‐Pappas(Children's Hospital of Philadelphia), Okan U. Elci(Westat (United States)), Daniel C. Chung(Penn Presbyterian Medical Center), Junwei Sun(Children's Hospital of Philadelphia), J. Fraser Wright(Children's Hospital of Philadelphia), Dominique Cross(Children's Hospital of Philadelphia), Puya Aravand(University of Pennsylvania), Laura Cyckowski(Children's Hospital of Philadelphia), Jeannette Bennicelli(University of Pennsylvania), Federico Mingozzi(Children's Hospital of Philadelphia), Alberto Auricchio(University of Naples Federico II), Eric A. Pierce(University of Pennsylvania), Jason Ruggiero(University of Pennsylvania), Bart P. Leroy(Ghent University Hospital), Francesca Simonelli(University of Campania "Luigi Vanvitelli"), Katherine A. High(Spark Therapeutics (United States)), Albert M. Maguire(University of Pennsylvania)
Cited by 455Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis